Physician profile
Pablo F Mora
NPI 1306836168
$1,335,662.48
in general payments reported to CMS, 2019-2025
46 companies · $276K in 2025
The $276K reported for 2025 was more than what 99% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $336K · 2020: $78K · 2021: $131K · 2022: $122K · 2023: $168K · 2024: $224K · 2025: $276K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $324K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $187K · Travel and Lodging: $107K · Food and Beverage: $23K · Consulting Fee: $22K · Honoraria: $3,540 · Education: $1,573.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $323,726.44 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $187,315.50 |
| Travel and Lodging | $106,754.57 |
| Food and Beverage | $23,231.35 |
| Consulting Fee | $21,993.75 |
| Honoraria | $3,540.00 |
| Education | $1,572.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $493,880.66 | 2019-2025 | Ozempic, Rybelsus, Victoza |
| Dexcom, INC. | $236,741.23 | 2019-2025 | Dexcom G7 Gss (161), Dexcom Stelo Glucose Biosensor, Dexcom G6 Transmitter |
| Insulet Corporation | $173,845.49 | 2019-2025 | Omnipod, Omnipod |
| Lilly USA, LLC | $99,937.99 | 2019-2025 | Lyumjev, Mounjaro, Jardiance |
| Abbott Laboratories | $96,016.52 | 2021-2025 | Freestyle Libre 3, Freestyle Libre |
| Merck Sharp & Dohme LLC | $60,299.64 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $55,711.47 | 2019-2025 | |
| Mannkind Corporation | $32,321.83 | 2019-2025 | Afrezza |
| Medtronic, INC. | $25,934.86 | 2022-2025 | Minimed 780g, Inpen Smart Insulin Delivery System |
| Valeritas, INC. | $22,080.54 | 2019 | |
| Novo Nordisk As | $9,721.05 | 2019 | |
| Janssen Pharmaceuticals, INC | $8,289.85 | 2019-2020 | |
| Xeris Pharmaceuticals, INC. | $4,344.49 | 2020-2025 | Gvoke Hypopen |
| Tandem Diabetes Care, INC. | $3,499.50 | 2019-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Zealand Pharma US, INC. | $2,642.03 | 2021-2022 |
Show all 45 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eli Lilly and Company | $2,641.36 | 2019-2025 | |
| Pfizer INC. | $1,993.64 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $923.48 | 2019-2022 | |
| Beta Bionics, INC. | $885.64 | 2023-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Boehringer Ingelheim Pharmaceuticals, INC. | $740.50 | 2019-2025 | Jardiance, Synjardy |
| Amarin Pharma, INC. | $679.90 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $471.55 | 2020 | |
| Sequel Med Tech, LLC | $395.65 | 2024-2025 | Twiist |
| Ascensia Diabetes Care US INC. | $357.33 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $329.05 | 2021-2025 | |
| Esperion Therapeutics, INC. | $199.40 | 2020-2021 | |
| Corcept Therapeutics | $135.13 | 2020-2025 | Korlym |
| Amgen INC. | $104.33 | 2020-2024 | Repatha |
| Amphastar Pharmaceuticals, INC. | $72.09 | 2024-2025 | |
| Alexion Pharmaceuticals, INC. | $62.23 | 2019 | |
| Lifescan, INC. | $57.38 | 2021-2022 | |
| Ibsa Pharma INC. | $50.20 | 2023-2024 | Tirosint, Licart, Tirosint |
| Medtronic Minimed, INC. | $48.50 | 2019-2020 | |
| Nevro Corp. | $33.98 | 2023 | Senza |
| Abbvie INC. | $33.23 | 2019-2024 | |
| Embecta Corp. | $30.70 | 2024 | Bd Nano 2nd Gen Pen Needle |
| Averitas Pharma INC. | $28.68 | 2025 | Qutenza |
| Rgh Enterprises LLC | $27.86 | 2025 | |
| Grt US Holding, INC. | $22.39 | 2021 | |
| Alnylam Pharmaceuticals INC. | $14.94 | 2022 | |
| Intuity Medical INC | $14.86 | 2022 | |
| Amneal Pharmaceuticals LLC | $14.59 | 2024 | Unithroid |
| Kowa Pharmaceuticals America, INC. | $11.86 | 2021 | |
| Antares Pharma, INC. | $11.63 | 2019 | |
| Cequr Corporation | $3.25 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$10,112.04 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pablo Mora listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.